Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

IFLO vs IART: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IART Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

IART Overall Winner 6-Pillar Tally: IFLO 1 – 5 IART Matrix Metrics: IFLO 2 – 8 IART

As of Nov 20, 2026, Integra LifeSciences Holdings (IART) is the stronger overall head-to-head candidate over VictoryShares International Free Cash Flow ETF (IFLO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IFLO carries a Unified Composite Score of 35.7/100 (SELL) at $33.75 (N/M Forward P/E, N/A operating margin), whereas IART carries 45.5/100 (HOLD) at $13.25 (5.6x Forward P/E, 9.9% operating margin).

  • Technical & Structure Timing Caution: IFLO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.5); meanwhile IART is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IFLO vs IART
IFLO NASDAQ
VictoryShares International Free Cash Flow ETF
Institutional Equity
$33.75
-2.02% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.76β · 18% Vol
Unified Composite Score
35.7 / 100 SELL
Tech 8.0 Fund 42.0 Flow 50.0 Mom 46.1
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.4%), weak momentum, RSI 29
RSI-14: 28.5 · SMA20: $35.82 · SMA50: $35.82
IART NASDAQ Head-to-Head Winner
Integra LifeSciences Holdings
Surgical & Medical Instruments & Apparatus
$13.25
-2.21% 1D
Market Cap $1.1B
TTM Revenue $1.66B
Forward P/E 5.6x
Beta / 30D Vol 1.54β · 60% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 43.0 Fund 53.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.2%), weak momentum, RSI 45
RSI-14: 44.7 · SMA20: $13.61 · SMA50: $14.08

6-Pillar Scorecard Institutional Category Breakdown (IFLO 1 – 5 IART)

Columns: Metric · IFLO · IART
1. Valuation Multiples IART
Forward P/E N/M 5.6x
Trailing P/E N/M 79.7x
PEG Ratio N/M 0.71x
EV / Revenue N/M 0.6x
2. Growth & Scale IART
Revenue Growth (YoY) N/A +2.3%
Earnings Growth (YoY) N/A +0.4%
TTM Revenue (USD) N/A $1.66B
Market Cap N/A $1.1B
3. Profitability & Quality IART
Gross Margin N/A 55.5%
Operating Margin N/A 9.9%
Net Profit Margin N/A 0.8%
Return on Equity (ROE) N/A 1.2%
4. Balance Sheet & Cash Flow IART
Cash Generation (TTM) N/A $72M
Cash Flow Margin N/A 4.3%
Net Cash / Leverage N/A ROE $77M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IFLO
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 57.4% (16th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat IART
OpEx & R&D Intensity N/A 45.6% of Rev ($755M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IFLO (2) vs IART (8)
Institutional Metric IFLO IART Criterion Row Edge
Market Capitalization
Scale
N/A $1.1B Larger Scale IART
Trailing P/E Ratio
Valuation
N/M 79.7x Lower Multiple IART
Forward P/E Ratio
Valuation
N/M 5.6x Lower Multiple IART
Revenue Growth (YoY)
Growth
N/A +2.3% Higher Growth IART
Operating Margin (TTM)
Profitability
N/A 9.9% Higher Margin IART
Net Profit Margin
Profitability
N/A 0.8% Higher Margin IART
Return on Equity (ROE)
Capital Efficiency
N/A 1.2% Higher ROE IART
52-Week Range Position
Momentum
63% ($27–$38) 39% ($9–$20) Stronger Trend IFLO
Beta / 30D Volatility
Risk Regime
0.76β · 18% Vol 1.54β · 60% Vol Lower Realized Risk IFLO
Unified Institutional Score
Composite Signal
35.7 / 100 (SELL) 45.5 / 100 (HOLD) Higher Composite IART
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.66B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 55.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.71x PEG · 0.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $72M ($77M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IART +13.85 pp
IFLO: -6.34% · IART: +7.51%
3M Horizon IFLO +10.11 pp
IFLO: -10.5% · IART: -20.61%
6M Horizon IFLO +14.4 pp
IFLO: +2.15% · IART: -12.25%
1Y Horizon IFLO +4.85 pp
IFLO: +23.68% · IART: +18.83%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IFLO vs IART. Trailing 12-month operating profitability (IFLO N/A vs IART 9.9%) and valuation multiples (IFLO N/M vs IART 5.6x Forward P/E) are benchmarked directly in Pillar 4 below.

IFLO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
IART ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.66B
Gross Margin55.5%
Op. Margin9.9%
ROE / Fwd P/E1.2% · 5.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IFLO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IFLO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IART BREAKDOWN
103d in phase · OBV NEUTRAL
Current IV 57.4%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact IART Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IFLO Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IART Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.1B market capitalization and 9.9% operating margin.
OpEx & R&D Reinvestment 45.6% of Rev ($755M)
90D Engineering Disclosures 0 Published

Investor FAQ IFLO vs IART Key Questions & Quantitative Answers

As of Nov 20, 2026, Integra LifeSciences Holdings (IART) is the stronger overall head-to-head candidate over VictoryShares International Free Cash Flow ETF (IFLO) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IFLO carries a Unified Composite Score of 35.7/100 (SELL) at $33.75 (N/M Forward P/E, N/A operating margin), whereas IART carries 45.5/100 (HOLD) at $13.25 (5.6x Forward P/E, 9.9% operating margin). Technical & Structure Timing Caution: IFLO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.5); meanwhile IART is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IART leads the Growth & Scale pillar: IFLO posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with IART at +2.3% YoY revenue growth and +0.4% YoY earnings growth on $1.66B TTM revenue (55.5% gross margin, 9.9% operating margin). On trailing 12-month operating scale, IFLO generates N/A in USD-normalized revenue versus $1.66B for IART. In operating R&D and SG&A reinvestment, IFLO deploys N/A (0 90-day corporate R&D disclosures) versus 45.6% of Rev ($755M) (0 disclosures) for IART.

IART screens cheaper on headline valuation multiples. IFLO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas IART trades at 5.6x Forward P/E, 79.7x Trailing P/E, 0.71x PEG, and 0.6x EV/Revenue (4.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IFLO (N/A ROE) versus IART (1.2% ROE) capital efficiency.

In options market volatility and institutional positioning, IFLO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.76β · 18% Vol realized risk). By comparison, IART carries 57.4% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.54β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.